Navigation Links
GeoVax Labs, Inc. Announces Results of 2009 Annual Shareholders Meeting
Date:6/23/2009

based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with a $17 million IPCAVD grant awarded in late 2007.

Safe Harbor Statement

All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions on the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward-looking statements involving certain risks and uncertainties including, without limitation, risks detailed in the Company's Securities and Exchange Commission filings and reports.


'/>"/>
SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
2. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
3. Excellent Results Received from GeoVaxs Full-Dose HIV/AIDS Vaccine Trial
4. GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update
5. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
6. GeoVax Labs, Inc. Selected by Georgia Bio as 2008 Deal of the Year Award Winner in Life Sciences Industry
7. Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program
8. GeoVax Vaccine Only 5th AIDS Vaccine Moving to Phase 2 Human Trials
9. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
10. GeoVax Secures $10 Million Financing Commitment
11. GeoVax Reports Progress on Its AIDS Vaccine Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... and LONDON , Nov. 25, ... AstraZeneca (NYSE: AZN ) today announced that AMAGINE-2 ... doses of brodalumab in more than 1,800 patients with moderate-to-severe ... Stelara ® (ustekinumab) and placebo at week 12. Brodalumab ... analysis group were each shown to be superior to Stelara ...
(Date:11/26/2014)... 26, 2014 China Nepstar Chain Drugstore Ltd. (NYSE: ... leading retail drugstore chain in China based on the ... financial results for the third quarter ended September 30, 2014. ... , Same store sales increased by 8.1% compared ... increased by 8.1% to RMB738.3 million (US$120.3 million) compared to ...
(Date:11/24/2014)... 2014 Luoxis Diagnostics, Inc., a subsidiary ... announced the presentation of three clinical and preclinical ... broadly applicable and robust research tool capable of ... response to injury, illness, or stress.  In all ... Luoxis, academic and pharmaceutical research partners, RedoxSYS was ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 11Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 2Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 4Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 5
(Date:11/26/2014)... (PRWEB) November 26, 2014 Call 866-997-4948 ... requirements or email the details on sales(at)researchmoz(dot)us , ... and drug discovery market 2014" with deep study of ... the result of high blood sugar. The global glucose ... linked to the growing number of diabetics in the ...
(Date:11/26/2014)... 2014 Louisiana Back Institute, leaders ... in minimally invasive spine surgery, announces today the ... rapidly growing provider network of orthopedic spine surgeons ... with the network’s continuing success providing the most ... residents who are suffering from orthopedic spine conditions ...
(Date:11/26/2014)... 2014 (HealthDay News) -- Youngsters who enter puberty early ... suggests. Early puberty was linked with a number ... and high anxiety levels, according to the researchers. Early ... conflict with family and peers, and having friends who ... Although the study found an association between early ...
(Date:11/26/2014)... News) -- Exposure to peanut protein in household dust ... with the skin condition eczema, a new study reveals. ... United States are allergic to peanuts. And severe eczema ... peanut allergy, the researchers noted. The new study ... The researchers examined the amount of peanut protein the ...
(Date:11/24/2014)... Recently, Fecbek.com ( http://www.fecbek.com ), a leading online shopping mall ... history of the Black Friday to its fans worldwide. ... is the Black Friday! It is a shopping day popular ... However, not everyone knows the history of the Special Friday. ... day. , The fourth Friday in November is the date ...
Breaking Medicine News(10 mins):Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:Infants With Eczema May Be More Prone to Peanut Allergy: Study 2
... Denise Mann HealthDay Reporter , MONDAY, July ... juice or capsules for the treatment and prevention of ... antibiotics may be more effective even if they contribute ... are less effective in the prevention, but do not ...
... 26, 2011] Antibiotic overuse and resistance have emerged as ... outbreak of Clostridium difficile infections, which often result from ... physicians and pharmacists with an education campaign that reduced ... Clinical Infectious Diseases and now available ...
... 2011Better data are needed to evaluate access to care ... as older African Americans, and to assess the benefits ... health information technology and access to multilevel diabetes education ... Management , a peer-reviewed journal published by Mary Ann ...
... July 25 (HealthDay News) -- Hospitalized patients who are able ... satisfied with their care, but one-fifth are not given the ... The authors of the new study compiled information on the ... three-year period, and had the patients rate their sense of ...
... MONDAY, July 25 (HealthDay News) -- The varicella vaccine has nearly ... study shows. The vaccine, introduced in a one-dose form ... all age groups and by 97 percent in young people 20 ... Immunization and Respiratory Diseases. "This is one of our ...
... Southwestern Medical Center researchers have narrowed the potential drug ... tumors are driven by a different hormonal pathway than ... known to stimulate the growth of the disease, advanced ... actually is driven by a pathway that circumvents the ...
Cached Medicine News:Health News:Antibiotics Beat Cranberries at Fighting Urinary Tract Infections in Study 2Health News:Antibiotics Beat Cranberries at Fighting Urinary Tract Infections in Study 3Health News:Simple guidelines decreased unnecessary antibiotic use in Quebec, Canada 2Health News:New data-based strategies and treatment models can improve diabetes care for older African-Americans 2Health News:Spiritual Talks May Boost Patients' View of Hospital Care 2Health News:Chickenpox Vaccine May Wipe Out Related Deaths: Study 2Health News:Chickenpox Vaccine May Wipe Out Related Deaths: Study 3Health News:UT Southwestern scientists discover new pathway to potential therapies for advanced prostate cancer 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: